Will Stryker’s MAKO Purchase Bring Disruption To The Ortho Industry?
Stryker’s adoption of MAKO’s RIO (Robotic-arm Interactive Orthopedic) system could give the global medical supplier a competitive edge over other orthopedic implant makers if the company can win converts to robotic surgery by leveraging its own experience in selling capital equipment.
You may also be interested in...
The approximately $52 million deal increases Stryker's offerings for limb-salvage procedures for cancer patients.
To stave off the sluggish growth in established markets, multinational medtechs not only are finding new business in countries with booming health care industries, but they’re also forging new ways to serve customers. Device companies now are pushing into services, such as disease management, and angling to compete more aggressively on pricing.
China’s MicroPort Scientific paid $290 million in cash for Wright Medical’s hip and knee business, which has a pipeline of products – including FDA approved implants – ready for sale in China’s growing orthopedics market. The acquisition pits MicroPort against multinationals that previously held an edge selling implants to Chinese patients and doctors who seem to favor devices that carry approval from the US FDA.